All‐cause mortality · hospital‐acquired pneumonia
Should short‐course antibiotic therapy showed no clear difference in mortality compared with prolonged‐course antibiotic therapy be used (moderate certainty).
1 finding from 1 review
Mortality MRSA · hospital‐acquired pneumonia
Should short‐course antibiotic therapy showed no clear difference in mortality MRSA compared with prolonged‐course antibiotic therapy be used (moderate certainty).
1 finding from 1 review
Mortality NF‐GNB · hospital‐acquired pneumonia
Should short‐course antibiotic therapy showed no clear difference in mortality NF‐GNB compared with prolonged‐course antibiotic therapy be used (low certainty).
1 finding from 1 review
All‐cause mortality · antibiotic use in acute respiratory infections
Procalcitonin algorithm leads to lower mortality compared with standard care (high certainty).
1 finding from 1 review
Mortality rate ( · children with acute pneumonia
Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).
1 finding from 1 review
Overall mortality · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis leads to lower overall mortality compared with placebo or no treatment (high certainty).
1 finding from 1 review
Overall mortality · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in overall mortality compared with no topical prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with a recent BSF independent of the presence or severity of CSF leakage
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review
All‐cause mortality; · Ventilator‐associated pneumonia
Monotherapy showed no clear difference in all‐cause mortality; compared with combination therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality; · Ventilator‐associated pneumonia
Carbapenems showed no clear difference in all‐cause mortality; compared with non‐carbapenems (moderate certainty).
1 finding from 1 review
Mortality within 28 days · people with acute respiratory infections
1 finding from 1 review
Mortality within 28 days · people with acute respiratory infections
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Meningitis‐related mortality · patients with a recent BSF independent of the presence or severity of CSF leakage
The intervention showed no clear difference in meningitis‐related mortality (moderate certainty).
1 finding from 1 review
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality in children with HIV infection ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ isoniazid prophylaxis only (low certainty).
1 finding from 1 review
Overall mortality ‐ topical prophylaxis versus placebo or no treatment · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in overall mortality ‐ topical prophylaxis versus placebo or no treatment compared with no topical prophylaxis (moderate certainty).
1 finding from 1 review